Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 37 (6), 599-604

Non-linear Kinetics of 4-methylpyrazole in Healthy Human Subjects

Clinical Trial

Non-linear Kinetics of 4-methylpyrazole in Healthy Human Subjects

D Jacobsen et al. Eur J Clin Pharmacol.


In order to evaluate the pharmacokinetic profile of the alcohol dehydrogenase inhibitor 4-methylpyrazole 4-MP, a placebo-controlled, double-blind, single-dose, randomized, sequential, ascending-dose "Phase-I study" was performed in healthy male volunteers at dose levels of 10 (n = 4), 20 (n = 4), 50 (n = 4) and 100 (n = 3). In the 10 and 20 group, the elimination of 4-MP from the plasma followed non-linear kinetics with mean rates of concentration decline of 3.66 and 5.05 mumol.l-1.h-1, respectively. In the two highest dose groups, the elimination also appeared to be non-linear although the patterns were not followed long enough to confirm this. The mean rates of concentration decline at the higher doses were significantly increased, up to 14.9 mumol.l-1.h-1 at 100 The average renal clearance of 4-MP was low, 0.016, and only 3% of the administered dose was excreted unchanged in the urine, indicating metabolism as the major route of elimination. Because of the apparently unusual kinetics following single dose treatment, thorough multiple dose studies need to be carried out to determine a safe dosage regimen for 4-MP.

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles


    1. Biochem Biophys Res Commun. 1972 Oct 6;49(1):283-91 - PubMed
    1. Eur J Clin Invest. 1977 Dec;7(6):487-90 - PubMed
    1. Alcohol Clin Exp Res. 1980 Jan;4(1):6-21 - PubMed
    1. Biochem Med. 1975 Aug;13(4):319-33 - PubMed
    1. Br J Clin Pharmacol. 1981 Nov;12(5):667-73 - PubMed

Publication types

LinkOut - more resources